20/20 Biolabs, Inc. - Common Stock (AIDX)

1.6400
-0.3500 (-17.59%)
NASDAQ · Last Trade: Mar 25th, 1:46 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program
Inflammatory Biomarker Tracking Predicted to Enhance 
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 24, 2026
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies
Protein Biomarkers May Play an Important Role in Overcoming Limitations of Circulating Tumor DNA for Screening Early-Stage Cancers
By 20/20 Biolabs Inc. · Via GlobeNewswire · March 12, 2026
20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities
Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights
By 20/20 Biolabs Inc. · Via GlobeNewswire · February 25, 2026
20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time
By 20/20 Biolabs Inc. · Via GlobeNewswire · February 20, 2026